Deferiprone Key 500 mg FC tablets
PDF Leaflet Revision Date: 27 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of iron overload in thalassaemia major.
Dosage (summary)
25 mg/kg three times daily, max 75 mg/kg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Aluminium-based antacids
- Vitamin C
Contraindications
- Hypersensitivity
- Neutropenia
- Agranulocytosis
- Pregnancy
- Breastfeeding
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Chromaturia
Counselling Points
- Monitor for signs of infection
- Avoid pregnancy
- Urine may discolor
Serious warnings
- Neutropenia
- Agranulocytosis
- Carcinogenic potential
Important Disclaimer
The Deferiprone Key 500 mg FC tablets professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
